
Opinion|Videos|August 13, 2024
Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data
Experts give an overview of the ASCO 2024 data.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
The phase 2
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
FDA approves cefepime and zidebactam for complicated UTI
3
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
4
Enzalutamide associated with greater cognitive decline than darolutamide in advanced prostate cancer
5












